Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Levosulpiride/risperidone

Hyperprolactinaemia

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mahesh DM, et al. Hyperprolactinemia in patients referred to a tertiary care hospital: A new drug mimics tumour levels. Indian Journal of Endocrinology and Metabolism 27 (Suppl. 1): S72-S73 abstr. ABS119, Dec 2023 [abstract] Mahesh DM, et al. Hyperprolactinemia in patients referred to a tertiary care hospital: A new drug mimics tumour levels. Indian Journal of Endocrinology and Metabolism 27 (Suppl. 1): S72-S73 abstr. ABS119, Dec 2023 [abstract]
Metadaten
Titel
Levosulpiride/risperidone
Hyperprolactinaemia
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56339-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Linezolid

Case report

Atezolizumab

Case report

Antineoplastics